101. Cognitive functions in survivors of primary central nervous system lymphoma.
- Author
-
Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, and Abrey LE
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Atrophy, Attention drug effects, Attention radiation effects, Brain pathology, Central Nervous System Neoplasms drug therapy, Central Nervous System Neoplasms radiotherapy, Cohort Studies, Combined Modality Therapy, Cranial Irradiation adverse effects, Female, Humans, Injections, Spinal, Lymphoma, Non-Hodgkin drug therapy, Lymphoma, Non-Hodgkin radiotherapy, Magnetic Resonance Imaging, Male, Memory drug effects, Memory radiation effects, Methotrexate administration & dosage, Methotrexate adverse effects, Middle Aged, Myelin Sheath pathology, Neuropsychological Tests, Prospective Studies, Quality of Life, Remission Induction, Survivors, Central Nervous System Neoplasms psychology, Cognition Disorders etiology, Lymphoma, Non-Hodgkin psychology
- Abstract
Background: The standard treatment for primary CNS lymphoma (PCNSL) involves high-dose methotrexate-based (MTX) chemotherapy and whole brain radiotherapy (WBRT). This combined regimen prolongs patient survival, but also carries a substantial risk for delayed neurotoxicity particularly in the elderly. However, cognitive outcome evaluations have not been included in most clinical trials., Objective: To assess cognitive functioning and quality of life in PCNSL survivors treated either with WBRT +/- MTX-based chemotherapy or chemotherapy alone., Methods: Twenty-eight PCNSL patients in disease remission received a post-treatment baseline neuropsychological evaluation, and a subset of patients were available for an 8-month follow-up evaluation. Assessment of quality of life and extent of white matter disease on MRI were also performed., Results: Patients displayed mild to moderate impairments across several cognitive domains. These were of sufficient severity to reduce quality of life in half of the patient sample. Comparisons according to treatment type revealed more pronounced cognitive impairment, particularly in the memory and attention/executive domains, among patients treated with WBRT +/- chemotherapy. Extent of white matter disease correlated with attention/executive, memory, and language impairment., Conclusions: PCNSL survivors treated with WBRT +/- chemotherapy displayed more pronounced cognitive dysfunction than patients treated with MTX-based chemotherapy alone.
- Published
- 2004
- Full Text
- View/download PDF